http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Davide Papis (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Hepatobiliary and pancreatic surgery in the elderly: Current status
Davide Papis,Alessio Vagliasindi,Pietro Maida 한국간담췌외과학회 2020 Annals of hepato-biliary-pancreatic surgery Vol.24 No.1
Hepato-pancreatico-biliary (HPB) surgery includes major hepatic resection and pancreatic surgery, both procedures are complex and have a potentially high complication rate. The presence of centers of excellence with a high patients volume has lowered the complication and increased the resection rate. Increased life expectancy and improved general health status have increased the number of elderly patients eligible for major surgery. Since old patients have more co-morbidities and decreased life expectancy, the benefit of these procedures need to be critically evaluated in this group. Analysis of the literature related to this argument demonstrated that pancreatoduodenectomy can be performed safely in selected elderly patients (70 years of age or older), with morbidity and mortality rates comparable those observed in younger patients. This aspect was also confirmed by cost analysis studies that reported similar data in both groups. Similar findings are also reported for major hepatic resection in elderly patients with either hepatocellular carcinoma (HCC), Klatskin tumor or gallbladder carcinoma. More studies are needed regarding the subgroup of very elderly patients (80 years or older). Nevertheless, those elderly patients who will benefit from surgery must be adequatelly selected.
-
Dupilumab Long-term Safety and Efficacy in Patients with Asthma: Liberty Asthma Traverse
( Hae Sim Park ),( Michael E. Wechsler ),( Linda B. Ford ),( Jorge F. Maspero ),( Ian D. Pavord ),( Yuji Tohda ),( David Langton ),( Christian Domingo ),( Alberto Papi ),( Arnaud Bourdin ),( Henrik Wa 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.0
Background Dupilumab, a fully human monocolonal antibody, blocks the shared receptor component for interleukin (IL) 4 and IL 13, key and central drivers of type 2 inflammation in multiple diseases. The efficacy and safety of dupilumab in asthma have been demonstrated up to 52 weeks in phase 2 and phase 3 studies. This open-label extension (OLE) study (NCT02134028) assessed long-term safety and efficacy of dupilumab in adult and adolescent patients who had completed a dupilumab asthma study (phase 2b DRI, phase 2 EXPEDITION, phase 3 QUEST, or phase 3 VENTURE). Methods Patients with moderate-to-severe or oral corticosteroid (OCS)-dependent severe asthma received add on subcutaneous dupilumab 300 mg every 2 weeks (q2w) up to 96 weeks. Treatment-emergent adverse events (TEAEs), annualized rate of severe asthma exacerbations (AER) during the treatment period, change from parent study baseline (PSBL) in forced expiratory volume in 1 second (FEV1), and biomarkers up to Week 96 were assessed. Results 2,282 patients were enrolled overall. Patient safety profile was consistent with the parent studies (Table). The low unadjusted AER and improvement in FEV1 observed in the parent studies were sustained during the OLE. Similar efficacy was seen in patients with elevated type 2 biomarkers from DRI/QUEST. By Week 96, blood eosinophils decreased to below-PSBL levels in patients from DRI/QUEST and were near-PSBL levels in patients from VENTURE; total IgE levels decreased by 82% (median percent change from PSBL). Conclusion Long-term use of dupilumab was well tolerated and showed sustained efficacy in asthma patients up to 96 weeks.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
